Table 3.
Change in the Cumulative Provoking Aspirin Dose during an Oral Aspirin Challenge
| Cumulative Provoking Aspirin Dose |
||||
|---|---|---|---|---|
| Number | Sex | Age (yr) | Placebo Phase | Omalizumab Phase |
| Developed aspirin tolerance | ||||
| 1 | M | 53 | 90 | 930* |
| 2 | F | 67 | 30 | 930* |
| 3 | M | 72 | 210 | 930* |
| 4 | M | 53 | 930 | 930* |
| 5 | F | 65 | 450 | 930* |
| 6 | F | 57 | 210 | 930* |
| 7 | F | 42 | 90 | 930* |
| 8 | M | 60 | 90 | 930* |
| 9 | F | 57 | 210 | 930* |
| 10 | M | 44 | 210 | 930* |
| Did not develop aspirin tolerance | ||||
| 11 | F | 21 | 90 | 210 |
| 12 | F | 60 | 210 | 210 |
| 13 | F | 49 | 90 | 210 |
| 14 | F | 52 | 210 | 210 |
| 15 | M | 44 | 90 | 210 |
| 16 | F | 40 | 90 | 210 |
Significance testing was performed using the McNemar test.
*
No symptoms were observed after the cumulative dose of aspirin (930 mg).